Racial Disparities in Systemic Sclerosis

Moore, Duncan F; Steen, Virginia D.

doi:10.1016/j.rdc.2020.07.009

Cited by 15 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As noted by Yin et al, the frequency of RP episodes may be modified by several disease-related factors. However, in a recent study, the duration and subtype of the disease did not affect Raynaud's Condition Score (RCS) diary outcomes, which quantify the daily frequency, duration, and severity of SSc-RP over a 1-to 2-week period (2). In our study, the duration of SSc and the time between onset of RP and the diagnosis of SSc were not statistically different between the treatment and placebo…”

Section: Replycontrasting

confidence: 64%

See 1 more Smart Citation

Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al

Yin

Liu

et al. 2023

Arthritis & Rheumatology

View full text Add to dashboard Cite

Section: Replycontrasting

confidence: 64%

“…First, the race and ethnicity of the participants were not reported. Racial and ethnic disparities in systemic sclerosis have been long recognized and should not be discounted (2). Furthermore, patient skin color might also affect the observation of RP, potentially influencing the number of RP episodes reported in the study.…”

mentioning

confidence: 97%

Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al

Yin

Liu

et al. 2023

Arthritis & Rheumatology

View full text Add to dashboard Cite

“…Main causes of death are lung and heart involvement which may occur early or late in the disease course [ 2 ]. Standardized mortality rates range from 2.82 to 3.64 in the most recent meta-analysis [ 3 ]. In addition, SSc imposes high burden in terms of quality of life and social cost.…”

Section: Introductionmentioning

confidence: 99%

Current Concepts on the Pathogenesis of Systemic Sclerosis

Truchetet

Brembilla²,

Chizzolini³

2021

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

From the clinical standpoint, systemic sclerosis (SSc) is characterized by skin and internal organ fibrosis, diffuse fibroproliferative vascular modifications, and autoimmunity. Clinical presentation and course are highly heterogenous and life expectancy variably affected mostly dependent on lung and heart involvement. SSc touches more women than men with differences in disease severity and environmental exposure. Pathogenetic events originate from altered homeostasis favored by genetic predisposition, environmental cues and a variety of endogenous and exogenous triggers. Epigenetic modifications modulate SSc pathogenesis which strikingly associate profound immune-inflammatory dysregulation, abnormal endothelial cell behavior, and cell trans-differentiation into myofibroblasts. SSc myofibroblasts show enhanced survival and enhanced extracellular matrix deposition presenting altered structure and altered physicochemical properties. Additional cell types of likely pathogenic importance are pericytes, platelets, and keratinocytes in conjunction with their relationship with vessel wall cells and fibroblasts. In SSc, the profibrotic milieu is favored by cell signaling initiated in the one hand by transforming growth factor-beta and related cytokines and in the other hand by innate and adaptive type 2 immune responses. Radical oxygen species and invariant receptors sensing danger participate to altered cell behavior. Conventional and SSc-specific T cell subsets modulate both fibroblasts as well as endothelial cell dysfunction. Beside autoantibodies directed against ubiquitous antigens important for enhanced clinical classification, antigen-specific agonistic autoantibodies may have a pathogenic role. Recent studies based on single-cell RNAseq and multi-omics approaches are revealing unforeseen heterogeneity in SSc cell differentiation and functional states. Advances in system biology applied to the wealth of data generated by unbiased screening are allowing to subgroup patients based on distinct pathogenic mechanisms. Deciphering heterogeneity in pathogenic mechanisms will pave the way to highly needed personalized therapeutic approaches.

show abstract

“…Examination of SES in systemic sclerosis suggests that higher wealth and more equitable access to health care services may mitigate increased mortality attributable to specific ethnic groups. 33 Current guidelines and management algorithms do not factor the effect of SES on the disease process. However, from the emerging data it is evident that SES plays an important role in health-related quality of life and clinical outcomes.…”

Section: Ses and Pahmentioning

confidence: 99%

The Impact of Socioeconomic, Racial, and Ethnic Disparities on Pulmonary Hypertension Diagnosis and Treatment

Talwar

Morel

Perez

et al. 2022

Advances in Pulmonary Hypertension

View full text Add to dashboard Cite

Health disparities have a major impact in the quality of life and level of clinical care received in minority populations in the United States. Underrepresented patients with pulmonary arterial hypertension (PAH) may be at risk for worse outcomes. Furthermore, advances in biomedical research have provided extensive knowledge on the genetic role in the pathogenesis of PAH but whether these also impact minorities is incompletely understood. Health disparities in patients with PAH create an enormous barrier in health care delivery. Understanding the contributors to health disparity represent a fundamental step towards personalized medicine and further improvement in PAH care.

show abstract

Racial Disparities in Systemic Sclerosis

Cited by 15 publications

References 27 publications

Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al

Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al

Current Concepts on the Pathogenesis of Systemic Sclerosis

The Impact of Socioeconomic, Racial, and Ethnic Disparities on Pulmonary Hypertension Diagnosis and Treatment

Contact Info

Product

Resources

About